| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 462.6K | $12.49M | - | |
| Other | 223.5K | $6.03M | - | |
| Other | 142.5K | $3.85M | - | |
| Other | 51.4K | $1.39M | - | |
| CFO | 18.1K | $490.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2021 | Andreas Maetzel73 | Senior Vice President, Medical | Sale+OE | 88,030 | $25.28 | $2,225,736.32 | - | -15.6% | -49.5% | |
| Apr 28, 2021 | Michael David Smith | Senior VP, Development | Sale+OE | 10,014 | $25.76 | $257,982.67 | - | -20.1% | -49.9% | |
| Apr 1, 2021 | Thomas Andrew Crockett72 | CEO | Sell | 10,000 | $27.44 | $274,436.23 | -5.9% | -12.7% | -45.4% | |
| Feb 23, 2021 | Christopher Yea53 | Chief Development Officer | Sell | 15,000 | $33.59 | $503,877.32 | -23.8% | - | - | |
| Feb 23, 2021 | Benjamin L Palleiko46 | CFO, Cbo & Secretary | Sale+OE | 29,642 | $33.59 | $995,561.82 | -31.3% | - | - | |
| Feb 23, 2021 | Thomas Andrew Crockett72 | CEO | Sell | 10,000 | $33.55 | $335,538.32 | -5.6% | - | - | |
| Feb 23, 2021 | Edward P. Feener72 | Chief Scientific Officer | Sell | 31,000 | $33.60 | $1,041,642.41 | -36.4% | - | - | |
| Jan 4, 2021 | Thomas Andrew Crockett72 | CEO | Sell | 10,000 | $18.19 | $181,904.14 | -5.1% | - | - | |
| Dec 30, 2020 | Benjamin L Palleiko46 | CFO, Cbo & Secretary | Sale+OE | 358 | $20.04 | $7,174.79 | -1.1% | - | - | |
| Nov 2, 2020 | Edward P. Feener72 | Chief Scientific Officer | Sell | 6,000 | $17.14 | $102,811.80 | -7.6% | - | - |